Veterinary Medicines

Eurican DAPPi-L

Not authorised
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Leptospira interrogans, serovar Canicola, strain 16070, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated
  • Canine adenovirus 2, strain DK13, Live
Download as PDF

Product identification

Medicine name:
Eurican DAPPi-L
Active substance:
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Leptospira interrogans, serovar Canicola, strain 16070, Inactivated
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated
  • Canine adenovirus 2, strain DK13, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain BA5, Live
    4.00
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain CAG2, Live
    4.90
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine parainfluenza virus, strain CGF 2004/75, Live
    4.70
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Leptospira interrogans, serovar Canicola, strain 16070, Inactivated
    1.00
    European Pharmacopoeia Unit(s)
    /
    1.00
    Dose
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain 16069, Inactivated
    1.00
    European Pharmacopoeia Unit(s)
    /
    1.00
    Dose
  • Canine adenovirus 2, strain DK13, Live
    2.50
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and suspension for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Bulgaria
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health France
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Bulgarian Food Safety Authority
Authorisation number:
  • 0022-2204
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Bulgarian (PDF)
Published on: 11/05/2022
Download